纤维化-4，天冬氨酸转氨酶 - 血小板比率指数和γ-谷氨酰转

StephenW

Eur J Gastroenterol Hepatol. 2019 Sep 3. doi: 10.1097/MEG.0000000000001520. [Epub ahead of print]
Fibrosis-4, aspartate transaminase-to-platelet ratio index, and gamma-glutamyl transpeptidase-to-platelet ratio for risk assessment of hepatocellular carcinoma in chronic hepatitis B patients: comparison with liver biopsy.
Kim MN1, Lee JH, Chon YE, Ha Y, Hwang SG.
Author information

1
    Department of Internal Medicine, CHA Bundang Medical Center, CHA Univesity, Seongnam, Republic of Korea.

Abstract
BACKGROUND AND AIMS:

It is well known that hepatocellular carcinoma (HCC) develops as a consequence of hepatic fibrosis progression. Thus, early identification of advanced liver fibrosis is very important. This study evaluated the prognostic value of FIB-4, the aspartate transaminase to-platelet ratio index (APRI), and the gamma-glutamyl transpeptidase-toplatelet ratio (GPR) for predicting HCC development using histological fibrosis stage as a reference in Asian chronic hepatitis B (CHB) patients.
METHODS:

A total of 444 CHB patients who underwent liver biopsy and serological tests for determining noninvasive serum fibrosis markers were enrolled. All patients were followed to monitor HCC development.
RESULTS:

The histological fibrosis stage showed best performance in predicting HCC development at 5 (area under the receiver operating characteristic curve [AUROC] = 0.783) and 7 years (AUROC = 0.766), followed by FIB-4 (AUROC = 0.753 at 5 years, 0.698 at 7 years), APRI (AUROC = 0.658 at 5 years, 0.572 at 7 years), and GPR (AUROC = 0.638 at 5 years, 0.603 at 7 years). When we classified risk groups according to the histological fibrosis stage (F4 vs. F0-3) and FIB-4 (FIB-4 ≥ 3.25 vs. FIB-4 < 3.25), patients in the high-risk group were found to have a significantly higher probability of developing HCC than those in the low-risk group (P=0.005 and 0.022, respectively, log-rank test).
CONCLUSION:

Our study demonstrated that FIB-4 is useful for the noninvasive prediction of HCC development, while APRI and GPR were less useful.

PMID:
    31490417
DOI:
    10.1097/MEG.0000000000001520

StephenW

Eur J Gastroenterol Hepatol。 2019年9月3日：doi：10.1097 / MEG.0000000000001520。 [印刷前的电子版]
纤维化-4，天冬氨酸转氨酶 - 血小板比率指数和γ-谷氨酰转肽酶 - 血小板比率用于慢性乙型肝炎患者肝细胞癌的风险评估：与肝活检比较。
Kim MN1，Lee JH，Chon YE，Ha Y，Hwang SG。
作者信息

1
    韩国城南市CHA大学CHA盆唐医疗中心内科

抽象
背景和目的：

众所周知，肝细胞癌（HCC）是肝纤维化进展的结果。因此，早期发现晚期肝纤维化非常重要。本研究评估了FIB-4，天冬氨酸转氨酶 - 血小板比值指数（APRI）和γ-谷氨酰转肽酶 - 血小板比值（GPR）预测HCC发展的预后价值，以组织学纤维化分期作为亚洲慢性肝炎的参考。 B（CHB）患者。
方法：

共招募了444名接受肝脏活组织检查和血清学检测以确定非侵袭性血清纤维化标志物的CHB患者。跟踪所有患者以监测HCC发展。
结果：

组织学纤维化阶段预测HCC发展的最佳表现为5（受试者工作特征曲线[AUROC] = 0.783）和7年（AUROC = 0.766），其次是FIB-4（AUROC = 0.753，5年，0.698）在7年时，APRI（5年时AUROC = 0.658，7年时为0.572）和GPR（5年时AUROC = 0.638,7岁时为0.603）。当我们根据组织学纤维化分期（F4与F0-3）和FIB-4（FIB-4≥3.25与FIB-4 <3.25）对风险组进行分类时，发现高风险组的患者有发生HCC的可能性显着高于低风险组（P = 0.005和0.022，对数秩检验）。
结论：

我们的研究表明，FIB-4可用于HCC发展的无创预测，而APRI和GPR则不太有用。

结论：
    31490417
DOI：
    10.1097 / MEG.0000000000001520